Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)

  Print      Mail a friend

Friday 11 January, 2019

Oxford BioDynamics

Board Transition

RNS Number : 7843M
Oxford BioDynamics PLC
11 January 2019
 

11 January 2019

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Board Transition

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that David Williams, Non-Executive Chairman, has indicated to the Board his desire to step down from his position following the Company's AGM in March 2019.

 

The Board has also been informed that Alison Kibble, Non-Executive Director, intends to step down from her role during the course of 2019, after over 11 years of service. Alison was appointed to OBD's Board as a Non-Executive Director in December 2007.

 

David and Alison will each continue in their respective role until the appointment of their replacement and will work closely with the Board to ensure a smooth transition. The Board has commenced the process of identifying successor independent non-executives and will update the market in due course.

 

David Williams, Chairman of Oxford BioDynamics, said: "It has been a pleasure to work with the Board and management team to serve shareholders as Oxford BioDynamics has transitioned to become a listed business. The Company has grown significantly since its IPO in December 2016, increasing its international footprint, its portfolio of intellectual property, and the range of global pharma and biopharma companies on its roster. Now is the right time for me to step down, as the Company enters the next phase of growth. I am confident that the Company will continue to go from strength to strength." 

 

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, added: "On behalf of the Board, I would like to thank David for his support and significant contribution to Oxford BioDynamics since joining the Board in 2016. David's input, as we have transitioned from a privately held company into a successful, growing AIM listed biotech, has proved invaluable. I would also like to thank Alison for her long service and valuable contributions over a period which has been transformational for the Company. Alison has made an invaluable contribution to the Company from the very first spin out from the University of Oxford."

 

-ENDS-

 

For further details please contact:

 

Oxford BioDynamics Plc

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

Shore Capital

Nominated Advisor and Broker

Stephane Auton

Edward Mansfield

+44 (0)20 7408 4090



FTI Consulting

Financial Public Relations Adviser

Brett Pollard

Natalie Garland-Collins

+44 (0)20 3727 1000

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOALLFFVLIIILIA

a d v e r t i s e m e n t